Clinical trials: Acute-On-Chronic Liver Failure
Acute-On-Chronic Liver Failure
Incidence and Predictors of Bleeding Diathesis Development Due to DIC in Cirrhosis and ACLF Patients Undergoing CRRT
ACLF and cirrhotic patient have deranged coagulation parameters and this coagulation parameters altered when this group of patients undergoing dialysis because of renal failure. this group of patients is also high risk of sepsis.
- Trial name
- NCT04960163
- Testing
- No intervention
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Acute-On-Chronic Liver Failure
TAK-242 in Patients With Acute Alcoholic Hepatitis
A phase 2a double-blind, randomized, placebo-controlled, multicenter, proof-of-concept study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of TAK-242 in subjects with acute decompensation of…
- Trial name
- NCT04620148
- Testing
- TAK-242
- Where
- 3 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- Akaza Bioscience Ltd
Hepatitis B, Acute-On-Chronic Liver Failure
Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF
This study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of HBV-related acute-on-chronic liver failure.
- Trial name
- HBV (NCT03920618)
- Testing
- Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Septic Shock and Acute Kidney Injury
Early Versus Late CRRT in ACLF Patients With Septic Shock and AKI
Consecutive patients with ACLF (Acute on Chronic Liver Failure) and septic shock with AKI (Acute Kidney Injury) who give written informed consent will be included in this prospective trial at ILBS.
- Trial name
- NCT03343340
- Testing
- Early CRRT, Late CRRT, Standard Medical Therapy
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Acute-On-Chronic Liver Failure
Umbilical Cord-derived Mesenchymal Stem Cell Infusion for Treating ACLF
This study is a multicenter, randomized, double-blind, placebo-controlled adaptive design Phase IIb/III clinical trial. It employs a seamless adaptive design, divided into Phase IIb and Phase III, focusing on patients with…
- Trial name
- MSCTACLF (NCT06884904)
- Testing
- Low-dose experimental group, High-dose experimental group
- Volunteers
- 96 people
- Sponsor
- National Engineering Center of Cell Products
Acute-On-Chronic Liver Failure
Efficacy and Safety of BMSCs (CG-BM1) for ACLF Patients
The goal of this clinical trial is to learn if CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection (hereinafter referred to as CG-BM1) can treat acute-on-chronic liver failure (ACLF) patients.
- Trial name
- NCT06740149
- Testing
- Bone marrow mesenchymal stem cells (low dose), Solvent of CG-BM1, Bone marrow mesenchymal stem cells (medium dose)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- GuangZhou Cellgenes Biotechnology Co., Ltd.
Liver Failure, Acute, Liver Failure, Acute on Chronic
HEpatic Regeneration With COupled Plasma Filtration and Adsorption for Liver Extracorporeal Detoxification
CPFA is currently used in the treatment of severe sepsis with the intention of removing the proinflammatory mediators from the systemic circulation.
- Trial name
- HERCOLE (NCT03312036)
- Testing
- Coupled plasma filtration and adsorption (CPFA)
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Acute on Chronic Hepatic Failure
Allogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure
Double-blind placebo randomized controlled trial evaluating the clinical efficacy of allogenic bone marrow derived mesenchymal stem cells in cirrhotic patients with acute-on-chronic liver failure
- Trial name
- Liveradvance (NCT02857010)
- Testing
- Allogenic mesenchymal stem cells
- Where
- Spain
- Volunteers
- 23 people
- Sponsor
- Pere Gines
Liver Failure, Acute on Chronic, Hepatic Encephalopathy
The Efficacy and Safety of Rifaximin Treatment
There will be 124 patients diagnosed as hepatitis B associated acute on chronic liver failure with mild to moderate hepatic encephalopathy will be enrolled in this study according to the inclusion and exclusion criteria, and will…
- Conditions
- Liver Failure, Acute on Chronic, Hepatic Encephalopathy, HBV, Hepatitis B
- Trial name
- NCT05786859
- Testing
- Rifaximin 200 mg, Standard Treatment without Rifaximin
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Sun Yat-sen University
Acute-On-Chronic Liver Failure
Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.
Acute on chronic liver failure patients are at high risk for nosocomial infections due to liver dysfunction, which impairs immune responses and increases vulnerability to infections.
- Trial name
- NCT06818565
- Testing
- Meropenem Injection, Ceftazidime-avibactam, Teicoplanin
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Acute-On-Chronic Liver Failure, Hepatitis B
Efficacy of Addition of Fecal Microbiota Transplant (FMT) and Plasma Exchange to Tenofovir in Comparison to Monotherapy With Tenofovir in ACLF-HBV
A randomized controlled trial to study the efficacy of addition of FMT \& plasma exchange to tenofovir compared to monotherapy with tenofovir in patients with HBV reactivation who develops Acute on chronic liver failure.
- Trial name
- NCT04431375
- Testing
- Plasma Exchange, Tenofovir, Fecal Mircobiota Transplantation
- Where
- India
- Volunteers
- 70 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Antifungal Agents, Invasive Fungal Infections
Anti-fungal Strategies in Acute-on-Chronic Liver Failure Patients
Early treatment of invasive fungal infections (IFI) may prevent undue mortality in acute on chronic liver failure (ACLF) patients.
- Conditions
- Antifungal Agents, Invasive Fungal Infections, Mycoses, Acute-On-Chronic Liver Failure
- Trial name
- NCT04157465
- Testing
- Treatment strategy trial
- Where
- India
- Volunteers
- 216 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Chronic Liver Failure
To Study the Immunomodulating Effects and Safety Profile of ω3 and ω6 PUFA Containing Intravenous Lipid Emulsion in Patients With Acute on Chronic Liver Failure
Study population: Patients admitted or seen in OPD (Out Patient Department), Department of Hepatology. Study design- Prospective Randomized Controlled Trial.
- Trial name
- NCT02691533
- Testing
- ω3 PUFA (Polyunsaturated fatty acids) (10% Omegavan 100 ml), ω6 PUFA (Polyunsaturated fatty acids) (10% Intralipid 100 ml)
- Where
- India
- Volunteers
- 90 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Acute Liver Failure, Acute Liver Injury, Drug Induced
miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial
The clinical trial will assess the safety of miroliverELAP for the treatment of acute liver failure, severe acute alcohol-associated hepatitis, or acute on chronic liver failure.
- Conditions
- Acute Liver Failure, Acute Liver Injury, Drug Induced, Acute on Chronic Liver Failure (ACLF), Acute Alcoholic Hepatitis
- Trial name
- NCT06285253
- Testing
- miroliverELAP treatment
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Miromatrix Medical Inc.
Acute-On-Chronic Liver Failure
Platelet Transfusion in HBV-related acute-on Chronic Liver Failure
Acute-on-chronic liver failure (ACLF) is a syndrome that has recently been recognized as encompassing acute deterioration of liver function in patients with pre-existing chronic liver disease.
- Trial name
- NCT03713489
- Testing
- platelet
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute-On-Chronic Liver Failure, Anticoagulant Adverse Reaction
COOLEY- Study: aCute On chrOnic Liver failurE Using the cYtosorb Device
A Prospective, Single-Center trial, in Patients With Acute on Chronic Liver Failure. Study of Standard Medical Care Plus CytoSorb® Compared to Standard Medical Care Alone in a historical group.
- Conditions
- Acute-On-Chronic Liver Failure, Anticoagulant Adverse Reaction, Sarcopenia, Ultrasonography
- Trial name
- COOLEY (NCT06079021)
- Testing
- CytoSorb
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- University Hospital, Antwerp
Liver Failure, Acute on Chronic, Liver Dysfunction
A Validation Cohort for ACLF Diagnosis and Prognosis
Acute on chronic liver failure (ACLF) is a distinct entity encompassing the acute deterioration of liver function, culminating in multiple organs failure and high short-term mortality.
- Trial name
- Ch-CANONIC-Val (NCT03641872)
- Testing
- Standary therapy
- Where
- 12 sites in China
- Volunteers
- 1,370 people
- Sponsor
- Hai Li
Acute-on-Chronic Liver Failure, Hepatitis B, Chronic
Prediction Model Based on Computed Tomography Liver Volume for the Short-term Mortality in Hepatitis B Related Acute-on-Chronic
HBV-related acute-on-chronic liver failure (HBV-ACLF) deteriorates rapidly with a high short-term mortality. Early identification and accurate prognostic prediction was critical to improve survival rate.
- Trial name
- NCT03977857
- Where
- China
- Volunteers
- 486 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Acute Hepatitis, Chronic Hepatitis
Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency
Evaluate on how well the ELAD system works in treating people with liver failure.
- Trial name
- ELAD (NCT00771446)
- Testing
- ELAD plus standard of care treatment, Standard of care treatment
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Vital Therapies, Inc.
Acute on Chronic Hepatic Failure
Hepa Wash Treatment of Patients With Acute-on-Chronic Liver Failure in Intensive Care Units
Patients with compensated chronic liver disease who have an episode of acute deterioration of liver function (acute-on-chronic liver failure) are known to have up to 90% mortality rate.
- Trial name
- HEPATICUS-1 (NCT01079091)
- Testing
- ADVOS (Hepa Wash), Standard Medical Therapy
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- Hepa Wash GmbH